Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_1

25%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

1(50.0%)

Phase 2Efficacy & side effects

1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(2)

Detailed Status

Completed2

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (50.0%)

Phase 21 (50.0%)

Trials by Status

completed250%

terminated250%

Recent Activity

0 active trials

Showing 4 of 4

terminated

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

NCT03462576

completed

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

NCT03439189

completedphase_2

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

NCT02960204

terminatedphase_1

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

NCT04803227

Clinical Trials (4)

Showing 4 of 4 trials

NCT03462576

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

Terminated

NCT03439189

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

Completed

NCT02960204Phase 2

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

Completed

NCT04803227Phase 1

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4